Immorta Bio appoints pharmaceutical veteran Dr. Armin Rath as Chief Business Officer to steer strategic partnerships and commercialization of its senolytic immunotherapy and personalized progenitor cell platforms.
Key points
- Dr. Armin Rath joins Immorta Bio from Cytovia Inc. to lead business development and strategic partnerships.
- The SenoVax platform employs first-in-class senolytic immunotherapy to target and clear senescent cells implicated in aging.
- StemCellRevivify uses personalized progenitor cells for organ-specific tissue rejuvenation, addressing conditions like liver failure and lung cancer.
Q&A
- What is senolytic immunotherapy?
- What are personalized progenitor cells?
- What role does the Chief Business Officer play?
- How do SenoVax and StemCellRevivify differ?
- What diseases could these platforms address?
